Colon Cancer

Paul F. Engstrom(Fox Chase Cancer Center), Christopher G. Willett
Journal of the National Comprehensive Cancer Network
September 1, 2009
10.6004/jnccn.2009.0056
Cited by 684

Related Papers

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
|Journal of Clinical Oncology|2009|507
Rectal Cancer
|Journal of the National Comprehensive Cancer Network|2009|441
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients
|Journal of Clinical Oncology|2005|419
Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response
|Journal of Clinical Oncology|2006|385